Enantioselective Pharmacokinetics of Venlafaxine in the Presence of CYP2D6 Inhibition: A Population Parent–Metabolite Modeling Approach
The Journal of Clinical Pharmacology · 2026-04 · 66 (4)
DOI: 10.1002/jcph.70194 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 21.04.2026. Verfasst von Brenda Cecília Mendes Alves und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Cytochrome P-450 CYP2D6 Inhibitors, Models, Biological, Paroxetine. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Bahia State Research Support Foundation (FAPESB), Fundação de Amparo à Pesquisa do Estado da Bahia.
Abstract (Originalsprache)
Venlafaxine, a serotonin‐norepinephrine reuptake inhibitor, is an antidepressant administered as a racemate of ( S )‐ and ( R )‐venlafaxine enantiomers, which differ in pharmacological activity. It is extensively metabolized, primarily via CYP2D6, to its major active metabolite, O ‐desmethylvenlafaxine. Variability in CYP2D6 activity, due to genetic polymorphisms or co‐administration with CYP2D6 inhibitors, can potentially alter exposure to both venlafaxine and O ‐desmethylvenlafaxine. This study aimed to quantify the impact of strong CYP2D6 inhibitor on the pharmacokinetics of venlafaxine and O ‐desmethylvenlafaxine and to evaluate whether dose adjustment is warranted when exposure to the active compounds is normalized by their relative pharmacodynamic potency. In a two‐phase crossover study, 24 subjects received a single oral dose of 150 mg racemic venlafaxine. Following a 2‐week washout period, a strong CYP2D6 inhibitor (paroxetine 20 mg) was administered daily for 10 days, with venlafaxine co‐administered on the final day. Enantiomer‐specific parent‐metabolite models were developed using nonlinear mixed‐effect modeling. A one‐compartment model with first‐order absorption, incorporating a first‐pass effect, and linear elimination was applied for both enantiomers. CYP2D6 inhibition reduced parent‐to‐metabolite conversion, with a 2.5‐fold greater effect on ( R )‐venlafaxine compared to ( S )‐venlafaxine. The co‐administration of CYP2D6 inhibitor reduced by ∼8% the potency‐adjusted exposure for norepinephrine and serotonin transporters. Although venlafaxine exposure increased under CYP2D6 inhibition, the magnitude of this effect was lower than that observed comparing CYP2D6 phenotypes. Therefore, dosing recommendations for venlafaxine in the presence of CYP2D6 inhibitors should be aligned with those for CYP2D6 intermediate metabolizers, for whom no dose adjustment is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.
- Department of Pharmaceutics, Center for Pharmacometrics & Systems Pharmacology, University of Florida, Orlando, FL, USA.
- School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
- School of Pharmaceutical Sciences of Ribeirao Preto, University of São Paulo, Ribeirão Preto, Brazil.
ORCID-Profile: Cacilda da Silva Souza, Natália Valadares de Moraes
Förderung
- Bahia State Research Support Foundation (FAPESB)
- Fundação de Amparo à Pesquisa do Estado da Bahia
Zitieren
APA
Alves, B. C. M., Yamamoto, P. A., Souza, C. D. S., Lanchote, V. L., Rocha, A., de Moraes, N. V., & Godoy, A. L. P. C. (2026). Enantioselective Pharmacokinetics of Venlafaxine in the Presence of CYP2D6 Inhibition: A Population Parent–Metabolite Modeling Approach. The Journal of Clinical Pharmacology, 66(4). https://doi.org/10.1002/jcph.70194
Vancouver
Alves BCM, Yamamoto PA, Souza CDS, Lanchote VL, Rocha A, de Moraes NV, et al. Enantioselective Pharmacokinetics of Venlafaxine in the Presence of CYP2D6 Inhibition: A Population Parent–Metabolite Modeling Approach. The Journal of Clinical Pharmacology. 2026;66(4). doi:10.1002/jcph.70194
BibTeX
@article{Alves2026,
author = {Alves, Brenda Cecília Mendes and Yamamoto, Priscila Akemi and Souza, Cacilda da Silva and Lanchote, Vera Lucia and Rocha, Adriana and de Moraes, Natália Valadares and Godoy, Ana Leonor Pardo Campos},
title = {Enantioselective Pharmacokinetics of Venlafaxine in the Presence of CYP2D6 Inhibition: A Population Parent–Metabolite Modeling Approach},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {4},
doi = {10.1002/jcph.70194}
}
EUVIMED